PRQR ProQR Therapeutics N.V. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1612940 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 4.69M | 2.88M | 3.82M | 4.52M | 4.31M | 3.84M | 6.30M | 4.45M |
| R&D expense | 9.92M | 11.08M | 11.41M | 12.32M | 10.61M | 9.41M | 7.05M | 9.28M |
| SG&A expense | 3.89M | 3.12M | 4.82M | 3.23M | 3.91M | 3.28M | 3.01M | 3.45M |
| Operating income | -9.10M | -11.28M | -12.25M | -10.82M | -10.08M | -8.72M | -3.60M | -8.07M |
| Pretax income | -8.92M | -11.01M | -12.16M | -10.08M | -9.30M | -8.11M | -2.89M | -7.66M |
| Income tax | 1,000 | 0 | 18,000 | — | 0 | 0 | -200,000 | 3,000 |
| Net income | -8.92M | -11.01M | -12.18M | -10.08M | -9.30M | -8.11M | -2.69M | -7.66M |
| EPS (basic) | — | -0.10 | -0.12 | -0.10 | — | -0.10 | -0.03 | -0.09 |
| EPS (diluted) | — | -0.10 | -0.12 | -0.10 | — | -0.10 | -0.03 | -0.09 |
| Weighted avg. shares (diluted) | — | 105.34M | 105.34M | 105.30M | — | 81.68M | 81.67M | 81.57M |
| Balance sheet | ||||||||
| Cash & equivalents | 92.41M | 106.88M | 119.77M | 132.41M | 149.41M | 89.40M | 78.97M | 85.71M |
| Short-term investments | — | — | — | — | — | — | 17.18M | 17.00M |
| Receivables | 6.80M | — | — | — | 3.75M | — | — | — |
| Current assets | 100.13M | 111.33M | 124.28M | 138.08M | 153.84M | 92.41M | 101.77M | 107.16M |
| PP&E, netmay include right-of-use assets (IFRS) | 12.63M | 13.02M | 13.26M | 13.61M | 14.11M | 14.44M | 16.29M | 16.72M |
| Total assets | 112.76M | 124.35M | 137.54M | 151.69M | 167.96M | 106.85M | 118.05M | 123.88M |
| Current liabilities | 32.44M | 33.14M | 33.09M | 33.72M | 38.90M | 39.64M | 37.28M | 34.42M |
| Short-term debt | 4.87M | 4.80M | 4.73M | 4.66M | 4.58M | 4.51M | 4.44M | 4.37M |
| Total liabilities | 63.38M | 67.28M | 70.55M | 72.75M | 79.40M | 81.87M | 85.20M | 89.06M |
| Shareholders' equity | 49.37M | 57.07M | 66.98M | 78.94M | 88.56M | 24.98M | 32.85M | 34.82M |
| Cash flow statement | ||||||||
| Operating cash flow | -13.36M | -12.23M | -11.40M | -15.80M | -9.35M | -5.66M | -6.26M | -15.13M |
| Capital expenditure | 526,000 | 169,000 | 101,000 | 224,000 | 133,000 | 286,000 | 267,000 | 732,000 |
| Free cash flow | -13.88M | -12.40M | -11.50M | -16.02M | -9.48M | -5.94M | -6.52M | -15.86M |
| Investing cash flow | -526,000 | -169,000 | -101,000 | -224,000 | -2.79M | 16.71M | -267,000 | -17.73M |
| Financing cash flow | -599,000 | -444,000 | -293,000 | -500,000 | 71.43M | -453,000 | -282,000 | -419,000 |
| Stock-based compensation | 1.23M | 1.12M | 909,000 | 758,000 | 568,000 | 612,000 | 628,000 | 736,000 |
Free plan shows the latest 8 periods; Pro shows all 32 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.